scholarly journals Trop2 promotes proliferation, invasion and EMT of nasopharyngeal carcinoma cells through the NF-κB pathway

RSC Advances ◽  
2017 ◽  
Vol 7 (84) ◽  
pp. 53087-53096
Author(s):  
Nan Cheng ◽  
Haixia Li ◽  
Junpeng Luo
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cell Surface ◽  
Surface Antigen ◽  
Trophoblast Cell ◽  
Carcinoma Cells ◽  
Cell Surface Antigen ◽  
Tumor Aggressiveness ◽  
Human Trophoblast ◽  
Transmembrane Glycoprotein ◽  
A Cell

Human trophoblast cell surface antigen 2 (Trop2), a cell surface transmembrane glycoprotein receptor, has been demonstrated to be closely associated with increasing tumor aggressiveness, metastasis and unfavorable prognosis.

scholarly journals Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2

iScience ◽  
2021 ◽  
Vol 24 (10) ◽  
pp. 103190
Author(s):  
Meng Sun ◽  
Helin Zhang ◽  
Min Jiang ◽  
Yan Chai ◽  
Jianxun Qi ◽  
...  
Keyword(s):  
Cell Surface ◽  
Surface Antigen ◽  
Trophoblast Cell ◽  
Cell Surface Antigen ◽  
Human Trophoblast ◽  
Cis And Trans ◽  
Structural Insights

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

2021 ◽  
Author(s):  
Shutan Liao ◽  
Bing Wang ◽  
Rong Zeng ◽  
Haifeng Bao ◽  
Xiaomin Chen ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cell Surface ◽  
Solid Tumors ◽  
Surface Antigen ◽  
Trophoblast Cell ◽  
Cell Surface Antigen ◽  
Recent Advances

A cell surface antigen expressed by astrocytes and their precursors

Glia ◽  
1993 ◽  
Vol 8 (1) ◽  
pp. 20-32 ◽  
Author(s):  
Vilma Szigeti ◽  
Robert H. Miller
Keyword(s):  
Cell Surface ◽  
Surface Antigen ◽  
Cell Surface Antigen ◽  
A Cell

Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis

2002 ◽  
Vol 30 (6) ◽  
pp. 537-545 ◽  
Author(s):  
Reiner Lammers ◽  
Christina Giesert ◽  
Frank Grünebach ◽  
Anke Marxer ◽  
Wichard Vogel ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Surface ◽  
Surface Antigen ◽  
Adhesion Molecule ◽  
Cellular Adhesion ◽  
Cell Surface Antigen ◽  
Cellular Adhesion Molecule ◽  
A Cell

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

1993 ◽  
Vol 11 (4) ◽  
pp. 738-750 ◽  
Author(s):  
E Oosterwijk ◽  
N H Bander ◽  
C R Divgi ◽  
S Welt ◽  
J C Wakka ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Monoclonal Antibody ◽  
Cell Surface ◽  
Cell Carcinoma ◽  
Surface Antigen ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Surface Antigen ◽  
Human Renal Cell Carcinoma ◽  
A Cell

PURPOSE To define the imaging and biodistribution characteristics of iodine 131-labeled monoclonal antibody (mAb) G250 (131I-mAbG250), which recognizes a cell-surface antigen expressed by human renal cell carcinoma (RCC). PATIENTS AND METHODS G250 is a cell-surface antigen recognized by mAbG250 expressed by RCC but not detected in normal kidney. Clear-cell RCC, the most frequent form of RCC, shows homogeneous expression of G250, whereas non-clear-cell RCC and cancers derived from other organs generally do not express G250. Expression in normal tissues is highly restricted and limited to large bile ducts and gastric epithelium. 131I-mAbG250 was administered intravenously (IV) to 16 patients with RCC 7 to 8 days before surgery at five dose levels, with at least three patients entered at each dose level. RESULTS Clear tumor images were observed in 12 patients with G250-positive tumors and in one of three patients with G250-negative tumors. Imaged lesions in the peritoneal cavity were confirmed at surgery. The smallest lesion visualized was 8 mm in diameter. The specificity of 131I-mAbG250 localization to tumor tissue was established by radioactivity measurements, autoradiography, and immunohistochemistry of biopsied tissues, and technetium 99-human serum albumin blood-flow studies. The fraction of the injected 131I-mAbG250 dose per gram tumor (%ID/g tumor) localized in G250-positive tumors showed a broad range, but reached levels as high as 0.02% to 0.12%. CONCLUSION 131I-mAbG250 localized specifically to G250 antigen-positive RCC and seems to have considerable potential as an imaging agent in RCC patients. 131I-mAbG250 uptake in the tumors, relative as well as absolute, are among the highest reported for tumor biopsies obtained 8 days after IV mAb administration. Based on the specific localization and high accumulation, mAb G250 may have therapeutic potential.

Sign in / Sign up

Export Citation Format

Share Document